Retatrutide
Also known as: LY3437943, Triple G
A triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Shows the highest weight loss of any obesity drug in trials.
Mechanism of Action
Triple agonism provides complementary metabolic effects: GLP-1 suppresses appetite, GIP enhances insulin sensitivity, glucagon increases energy expenditure and fat oxidation.
Dosing Protocol
Titration from 1mg weekly, increasing monthly to 4mg, 8mg, up to 12mg weekly.
Open peptide calculatorReconstitution
Research-grade: 5mg vial + 2mL BAC water.
Storage
Refrigerate 2-8°C. Do not freeze.
Side Effects
- ●Nausea
- ●Diarrhea
- ●Vomiting
- ●Constipation
- ●Injection site reactions
Key Research Findings
- ●Phase 2: up to 24.2% body weight loss at 48 weeks (highest recorded)
- ●Superior glycemic control vs semaglutide in early data
- ●Significant reduction in liver fat content
Latest Verified Lab Report
No lab reports available for Retatrutide yet.
Community-funded testing results will appear here.
Vendor Trust Leaderboard
Trust leaderboard coming soon.
Vendor rankings based on verified lab test results.
Research Use Only
This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.